Calidi Biotherapeutics Enters Loan Agreement
Ticker: CLDWW · Form: 8-K · Filed: Jul 8, 2024 · CIK: 1855485
| Field | Detail |
|---|---|
| Company | Calidi Biotherapeutics, Inc. (CLDWW) |
| Form Type | 8-K |
| Filed Date | Jul 8, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $600,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financing, debt, material-definitive-agreement
Related Tickers: CLDI
TL;DR
Calidi just took out a new loan, details in the 8-K.
AI Summary
On July 1, 2024, Calidi Biotherapeutics, Inc. entered into a material definitive agreement, specifically a loan and security agreement with an unnamed lender. This agreement creates a direct financial obligation for the company, the terms of which are detailed in the filing.
Why It Matters
This filing indicates Calidi Biotherapeutics has secured new financing, which could impact its operational capacity and future development projects.
Risk Assessment
Risk Level: medium — Entering into new debt obligations can increase financial risk for a company, especially if the terms are unfavorable or if revenue generation is uncertain.
Key Players & Entities
- Calidi Biotherapeutics, Inc. (company) — Registrant
- July 1, 2024 (date) — Date of earliest event reported
- First Light Acquisition Group, Inc. (company) — Former company name
FAQ
What is the specific amount of the loan secured by Calidi Biotherapeutics?
The filing does not specify the exact dollar amount of the loan in the provided text.
Who is the lender in the new loan and security agreement?
The identity of the lender is not disclosed in the provided text of the filing.
What is the interest rate associated with the new loan?
The interest rate for the loan is not detailed in the provided text.
What collateral is being used for the loan and security agreement?
The specific collateral pledged for the loan is not mentioned in the provided text.
When was Calidi Biotherapeutics, Inc. formerly known as First Light Acquisition Group, Inc.?
The date of the name change from First Light Acquisition Group, Inc. to Calidi Biotherapeutics, Inc. was April 6, 2021.
Filing Stats: 644 words · 3 min read · ~2 pages · Grade level 10.2 · Accepted 2024-07-08 16:30:15
Key Financial Figures
- $0.0001 — ch Registered Common stock, par value $0.0001 per share CLDI NYSE American LLC
- $600,000 — oan the Company the principal amount of $600,000 pursuant to the terms of the promissory
Filing Documents
- form8-k.htm (8-K) — 46KB
- ex10-1.htm (EX-10.1) — 7KB
- ex10-2.htm (EX-10.2) — 2KB
- ex10-1_001.jpg (GRAPHIC) — 326KB
- ex10-1_002.jpg (GRAPHIC) — 496KB
- ex10-1_003.jpg (GRAPHIC) — 263KB
- ex10-1_004.jpg (GRAPHIC) — 80KB
- ex10-1_005.jpg (GRAPHIC) — 278KB
- ex10-1_006.jpg (GRAPHIC) — 447KB
- ex10-1_007.jpg (GRAPHIC) — 131KB
- ex10-2_001.jpg (GRAPHIC) — 276KB
- ex10-2_002.jpg (GRAPHIC) — 447KB
- ex10-2_003.jpg (GRAPHIC) — 131KB
- 0001493152-24-026477.txt ( ) — 4234KB
- cldi-20240701.xsd (EX-101.SCH) — 4KB
- cldi-20240701_def.xml (EX-101.DEF) — 26KB
- cldi-20240701_lab.xml (EX-101.LAB) — 36KB
- cldi-20240701_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CALIDI BIOTHERAPEUTICS, INC. Dated: July 8, 2024 By: /s/ Andrew Jackson Name: Andrew Jackson Title: Chief Financial Officer